194938-88-0

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2,6-difluoro-4-hydroxybenzoate is used as a preservative and stabilizer in pharmaceutical formulations for its antimicrobial properties, ensuring the stability and safety of the products.
Used in Cosmetics and Personal Care Products:
Methyl 2,6-difluoro-4-hydroxybenzoate is used as a preservative in cosmetics and personal care products to prevent microbial contamination and extend the shelf life of these products.
Used in Topical Medications:
Methyl 2,6-difluoro-4-hydroxybenzoate is used as an active ingredient in topical medications due to its anti-inflammatory and analgesic properties, providing relief from pain and inflammation.
Used in Skincare Formulations:
Methyl 2,6-difluoro-4-hydroxybenzoate is used in skincare formulations for its antimicrobial and anti-inflammatory properties, promoting skin health and preventing infections.
It is important to handle and store Methyl 2,6-difluoro-4-hydroxybenzoate with care, as it can be harmful if ingested or comes into contact with the skin or eyes.

Upstream product

• 84937-82-6 methyl 2,6-difluoro-4-methoxybenzoate 
• 67-56-1 methanol 
• 214917-68-7 2,6-difluoro-4-hydroxybenzoic acid 
• 123843-57-2 2,6-difluoro-4-hydroxybenzonitrile 

Relevant academic research and scientific papers

TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY

The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.

NOVEL 5-AMINO-2-THIOIMIDAZOLE COMPOUNDS AND THEIR USE

The present invention is directed to novel compounds of formula (I) pharmaceutically acceptable salts or solvates thereof, and their use.

Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance

The role of the G-protein-coupled bile acid receptor TGR5 in various organs, tissues, and cell types, specifically in intestinal endocrine L-cells and brown adipose tissue, has made it a promising therapeutical target in several diseases, especially type-2 diabetes and metabolic syndrome. However, recent studies have shown deleterious on-target effects of systemic TGR5 agonists. To avoid these systemic effects while stimulating glucagon-like peptide-1 (GLP-1) secreting enteroendocrine L-cells, we have designed TGR5 agonists with low intestinal permeability. In this article, we describe their synthesis, characterization, and biological evaluation. Among them, compound 24 is a potent GLP-1 secretagogue, has low effect on gallbladder volume, and improves glucose homeostasis in a preclinical murine model of diet-induced obesity and insulin resistance, making the proof of concept of the potential of topical intestinal TGR5 agonists as therapeutic agents in type-2 diabetes.

IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE

The present invention is directed to novel compounds of formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.

AROMATASE INHIBITOR

There is provided a compound of formula (I) wherein Z is selected from N and CR22, wherein R22 is H or a bond with D, wherein D is selected from a bond, C=O, and linear or branched hydrocarbon groups having a carbon chain of from 1 t

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS

The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can a

NEW BENZIMIDAZOLE DERIVATIVES

The invention is concerned with novel benzimidazole derivatives of Formula (I) wherein A, n and R1 to R7 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds act on Farnesyl X receptor (FXR) and against cholesterol and lipid illnesses, diabetes, obesity, psoriasis, cancer, osteoporosis, Parkinson's and Alzheimer's disease.

SYNTHESIS OF PYRAZOLES

The present invention provides methods of making HCl salts, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other

NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS

The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

Carboxylate derivatives comprising an ether group and liquid crystal composition comprising the same

A compound represented by the following general formula (I), a liquid crystal composition comprising the same, and a liquid crystal element using this liquid crystal composition. (wherein B1 and B2 represent independently a trans-1,4-cyclohexylene group o